Compare NEOG & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | ANAB |
|---|---|---|
| Founded | 1981 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 1989 | 2017 |
| Metric | NEOG | ANAB |
|---|---|---|
| Price | $6.05 | $44.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $8.83 | ★ $63.80 |
| AVG Volume (30 Days) | ★ 3.5M | 751.8K |
| Earning Date | 01-09-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $886,886,000.00 | $169,467,000.00 |
| Revenue This Year | N/A | $135.45 |
| Revenue Next Year | $1.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 196.42 |
| 52 Week Low | $3.87 | $12.21 |
| 52 Week High | $13.51 | $45.32 |
| Indicator | NEOG | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 72.08 |
| Support Level | $5.82 | $40.52 |
| Resistance Level | $6.08 | $45.32 |
| Average True Range (ATR) | 0.32 | 2.65 |
| MACD | 0.00 | 0.35 |
| Stochastic Oscillator | 63.68 | 85.66 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).